Opus Point Partners Management as of March 31, 2018
Portfolio Holdings for Opus Point Partners Management
Opus Point Partners Management holds 50 positions in its portfolio as reported in the March 2018 quarterly 13F filing
Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
---|---|---|---|---|---|
Proshares Tr pshs ult nasb (BIB) | 26.7 | $14M | 248k | 55.06 | |
Nektar Therapeutics (NKTR) | 4.9 | $2.5M | 23k | 106.27 | |
SPDR S&P Biotech (XBI) | 4.1 | $2.1M | 24k | 87.73 | |
Mettler-Toledo International (MTD) | 4.0 | $2.1M | 3.6k | 575.13 | |
iShares NASDAQ Biotechnology Index (IBB) | 3.9 | $2.0M | 19k | 106.72 | |
Alnylam Pharmaceuticals (ALNY) | 3.2 | $1.6M | 14k | 119.08 | |
Alexion Pharmaceuticals | 3.0 | $1.5M | 14k | 111.46 | |
Vertex Pharmaceuticals Incorporated (VRTX) | 3.0 | $1.5M | 9.2k | 162.94 | |
Alkermes (ALKS) | 2.8 | $1.4M | 24k | 57.95 | |
Agios Pharmaceuticals (AGIO) | 2.6 | $1.3M | 16k | 81.80 | |
Illumina (ILMN) | 2.5 | $1.3M | 5.5k | 236.47 | |
Seattle Genetics | 2.2 | $1.1M | 21k | 52.35 | |
Qiagen Nv | 2.1 | $1.1M | 33k | 32.32 | |
Ionis Pharmaceuticals (IONS) | 2.0 | $1.0M | 23k | 44.09 | |
Amgen (AMGN) | 1.9 | $990k | 5.8k | 170.54 | |
Biogen Idec (BIIB) | 1.9 | $963k | 3.5k | 273.81 | |
Incyte Corporation (INCY) | 1.8 | $940k | 11k | 83.35 | |
Regeneron Pharmaceuticals (REGN) | 1.8 | $903k | 2.6k | 344.39 | |
BioMarin Pharmaceutical (BMRN) | 1.7 | $864k | 11k | 81.08 | |
Celgene Corporation | 1.7 | $849k | 9.5k | 89.26 | |
Fibrogen (FGEN) | 1.7 | $845k | 18k | 46.22 | |
ACADIA Pharmaceuticals (ACAD) | 1.6 | $825k | 37k | 22.46 | |
Loxo Oncology | 1.6 | $796k | 6.9k | 115.36 | |
Clovis Oncology | 1.4 | $686k | 13k | 52.77 | |
Karyopharm Therapeutics (KPTI) | 1.3 | $671k | 50k | 13.42 | |
Tesaro | 1.3 | $657k | 12k | 57.13 | |
Checkpoint Therapeutics | 1.0 | $495k | 113k | 4.39 | |
Akebia Therapeutics (AKBA) | 0.9 | $477k | 50k | 9.54 | |
Proqr Thrapeutics N V shs euro (PRQR) | 0.9 | $472k | 154k | 3.07 | |
Pacira Pharmaceuticals (PCRX) | 0.8 | $389k | 13k | 31.12 | |
Ultragenyx Pharmaceutical (RARE) | 0.7 | $372k | 7.3k | 51.02 | |
Adamas Pharmaceuticals | 0.7 | $359k | 15k | 23.93 | |
Axsome Therapeutics (AXSM) | 0.6 | $327k | 134k | 2.45 | |
Bio-techne Corporation (TECH) | 0.6 | $303k | 2.0k | 150.82 | |
United Therapeutics Corporation (UTHR) | 0.6 | $290k | 2.6k | 112.45 | |
Grifols S A Sponsored Adr R (GRFS) | 0.6 | $285k | 13k | 21.23 | |
Intrexon | 0.6 | $283k | 19k | 15.32 | |
Iqvia Holdings (IQV) | 0.6 | $283k | 2.9k | 97.96 | |
Charles River Laboratories (CRL) | 0.6 | $279k | 2.6k | 106.77 | |
Avexis | 0.6 | $281k | 2.3k | 123.52 | |
Gilead Sciences (GILD) | 0.5 | $276k | 3.7k | 75.27 | |
Intercept Pharmaceuticals In | 0.5 | $277k | 4.5k | 61.61 | |
Neurocrine Biosciences (NBIX) | 0.5 | $268k | 3.2k | 82.92 | |
Paratek Pharmaceuticals | 0.5 | $260k | 20k | 13.00 | |
Medicines Company | 0.5 | $231k | 7.0k | 33.00 | |
Bluebird Bio (BLUE) | 0.4 | $226k | 1.3k | 170.44 | |
Recro Pharma | 0.3 | $139k | 13k | 11.02 | |
Contrafect | 0.2 | $122k | 75k | 1.63 | |
Progenics Pharmaceuticals | 0.2 | $81k | 11k | 7.44 | |
Scynexis | 0.1 | $45k | 33k | 1.35 |